M A R C Y R L

About
Marcyrl Pharma

Marcyrl Pharmaceutical Industries is an Egyptian pharmaceutical company established in 1998. It is dedicated to manufacturing and marketing high-quality, affordable medications. Marcyrl focuses on a wide range of therapeutic areas including cardiology, Dermatology, and neurology, aiming to improve healthcare outcomes both locally and internationally. The company is known for its commitment to innovation, adhering to stringent quality standards, and contributing to the pharmaceutical sector's growth in Egypt and beyond.

Marcyrl gained a certificate of Good Manufacturing Practice (GMP), which is issued to a manufacturer by the national competent authority inspected if the outcome of the inspection confirms that the manufacturer complies with the principles of Good Manufacturing Practice, as provided by European Union legislation

Marcyrl gained the ISO accreditation that an organization has met the requirements of the international standard for management systems certification bodies and is qualified to audit and certify management systems. It provides confidence in the certifications provided and ensures impartiality and competence.

Marcyrl got an accreditation from The Saudi Food and Drug Authority (SFDA) Partnering with the SFDA allows our company to participate in advancing the healthcare looks good. It provides opportunities to collaborate on research and development initiatives and introduce innovative products.

Why partner with Marcyrl

A Wide portfolio including a niche
in hormonal and respiratory

325 SKUs mainly in chronic disease areas; 300 SKUs in the pipeline A portfolio spanning 15 TAs, in particular female health/fertility, cardiovascular, urology, neuroscience, gastroenterology, etc. Niche in novel, high-complexity products (in particular hormonal, respiratory)

Why partner with Marcyrl

Wide portfolio including niche
in hormonal and respiratory products

Top-notch R&D and manufacturing capabilities with EU GMP-certified facilities Cost competitiveness built on world-class procurement and lean operations – Track record of effective cost containment despite sharp currency devaluation 2017-2021; Leadership in the tender market (11% of sales in 2021)

Why partner with Marcyrl

Track record of registering and
commercializing in export markets

Existing export footprint
in 23 countries outside of Egypt
107 successful registrations in export markets,
106 products under registration

Why partner with Marcyrl

Strong management team, backed by
leading institutional investors

Experienced management with diverse expertise
Entry of DPI and Amethis in 2023
- combined AUM of USD 3.6 billion,
Africa focused with strong pharma exposure